Contraindications: Not indicated for use in individuals with androgen-sensitive malignancies, severe hepatic or renal impairment, active cardiovascular disease, or untreated hypercholesterolaemia. Contraindicated in women due to virilisation risk at the dose levels required for competitive physique outcomes.
Side Effects: Androgenic effects — accelerated scalp hairline recession in genetically predisposed individuals, sebaceous gland overactivity leading to acne, and elevated aggression — are dose-dependent and occur at the elevated weekly totals used in professional protocols. Cardiovascular risk includes HDL suppression and LDL elevation, which are amplified when Drostanolone Propionate is co-administered with other androgens across extended prep blocks.
Monitoring: Professional users should obtain a full lipid panel, haematocrit, haemoglobin, liver enzymes (ALT/AST), and PSA at baseline and at mid-cycle (approximately week 6–8). Blood pressure should be self-monitored biweekly throughout the preparation block. Haematocrit values approaching 52% warrant dose review and possible therapeutic phlebotomy.
PCT: Because Drostanolone Propionate suppresses the hypothalamic-pituitary-gonadal axis at professional dose levels, post-cycle therapy is mandatory. The rapid clearance of the propionate ester — typically within 5–7 days of the last injection — allows PCT initiation earlier than with long-ester compounds. A standard SERM-based protocol (Nolvadex or Clomid) is the minimum requirement; experienced competitors with extended prep-block exposure often incorporate hCG in the final week before PCT commencement.